Pharmacological treatment of generalized anxiety disorder
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Generalized anxiety disorder (GAD) is a chronic, relapsing, debilitating disorder, associated with markedly impaired social and occupational functioning. Pharmacological treatment is considered standard care and several drug classes are now FDA approved for the treatment of GAD. While there are clear data for the efficacy of short-term acute treatment, long-term treatment and treatment-resistant GAD remain challenging. AREAS COVERED: This article describes current pharmacological treatment options for GAD, with focus on benzodiazepines, azapirones, antidepressants and anticonvulsant and antipsychotic drugs. Recent findings from placebo-controlled clinical trials are reviewed and evidence-based clinical implications are discussed. A PubMed search was completed using the terms: 'generalized anxiety disorder AND treatment' and 'generalized anxiety disorder AND therapy'. Additional pivotal trials were included for a historical perspective (older landmark trials that established efficacy and safety for older drug classes in the treatment of GAD). EXPERT OPINION: Efficacy for treatment of GAD has been established for several different drug classes. At present, based on clear efficacy and good tolerability, first-line treatment with either a selective serotonin reuptake inhibitor (SSRI) or a serotonin-norepinephrine reuptake inhibitor (SNRI) is indicated. If an initial, at least moderate, clinical response is achieved under antidepressant therapy, treatment should be at least continued for 12 months.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Major Depressive Disorder Treatment Guidelines in America and Europe
Davidson, J. R. T. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.9058se1c.04gry · Cited by 344
The epidemiology of generalized anxiety disorder
Kessler, R. C., Keller, M. B., & Wittchen, H.-U. (2001) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(05)70204-5 · Cited by 337 · cited 2×
“More than 90% of patients with GAD present with an additional psychiatric diagnosis, and the ancillary condition is MDD in 48% of patients [3,5].”
BackgroundPsychological therapies for generalised anxiety disorder
Hunot, V., Churchill, R., Teixeira, V., & Silva de Lima, M. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001848.pub4 · Cited by 315 · cited 1×
“A systematic review of several studies assessing psychotherapy in patients with GAD showed that CBT-based psychotherapy was effective in improving anxious symptoms in the short term in patients with GAD [37].”
BackgroundAntidepressant Discontinuation Syndromes: Clinical Relevance, Prevention and Management
Haddad, P. M. (2001) · Drug Safety · doi:10.2165/00002018-200124030-00003 · Cited by 214 · cited 2×
“Abrupt discontinuation of venlafaxine also precipitates a discontinuation syndrome with similar or greater frequency than does paroxetine [42].”
BackgroundMcIntyre, A., Gendron, A., & McIntyre, A. (2007) · Depression and Anxiety · doi:10.1002/da.20275 · Cited by 145
Bandelow, B., Chouinard, G., Bobes, J., Ahokas, A., Eggens, I., Liu, S., & Eriksson, H. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709990423 · Cited by 142
Current Considerations in the Treatment of Generalized Anxiety Disorder
Katzman, M. A. (2009) · CNS Drugs · doi:10.2165/00023210-200923020-00002 · Cited by 128 · cited 2×
“The atypical antipsychotics (AAPs) have improved the pharmacotherapy of schizophrenia and other schizoaffective disorders but may prove also to be efficacious as adjunctive therapy or possibly monotherapy for GAD [71-74].”
BackgroundStahl, S. M. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0901 · Cited by 88 · cited 2×
“Their rapid onset and tolerability make them conducive to alleviating anxious symptoms when immediate anxiolytic effects are desired [16,17].”
BackgroundRemission Rates in Patients With Anxiety Disorders Treated With Paroxetine
Ballenger, J. C. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n1216 · Cited by 82
Is the Cutoff to Define Remission on the Hamilton Rating Scale for Depression Too High?
Zimmerman, M., Posternak, M. A., & Chelminski, I. (2005) · Journal of Nervous & Mental Disease · doi:10.1097/01.nmd.0000154840.63529.5d · Cited by 79 · cited 1×
“Aside from the obvious issue of potential dependence with prolonged use, benzodiazepines are also not desirable first-line therapies owing to the potential for withdrawal syndromes and rebound effects upon abrupt discontinuation [5,20,21].”
Background
Cited by
The Forced Swim Test as a Model of Depressive-like Behavior
Yankelevitch-Yahav, R., Franko, M., Huly, A., & Doron, R. (2015) · Journal of Visualized Experiments · doi:10.3791/52587 · Cited by 754
50 years of hurdles and hope in anxiolytic drug discovery
Griebel, G., & Holmes, A. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4075 · Cited by 414
Physical activity and anxiety: A perspective from the World Health Survey
Stubbs, B., Koyanagi, A., Hallgren, M., Firth, J., Richards, J., Schuch, F., Rosenbaum, S., Mugisha, J., Veronese, N., Lahti, J., et al. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.10.028 · Cited by 324
Treating comorbid anxiety and depression: psychosocial and pharmacological approaches
Coplan, J. D. (2015) · World Journal of Psychiatry · doi:10.5498/wjp.v5.i4.366 · Cited by 207
Treatment of Borderline Personality Disorder: Is Supply Adequate to Meet Public Health Needs?
Iliakis, E. A., Sonley, A. K. I., Ilagan, G. S., & Choi-Kain, L. W. (2019) · Psychiatric Services · doi:10.1176/appi.ps.201900073 · Cited by 161
Metadata
- Authors
- Reinhold, J. A., Mandos, L. A., Rickels, K., & Lohoff, F. W.
- Venue
- Expert Opinion on Pharmacotherapy
- Publisher
- Informa Healthcare
- Published
- 2011-09-28
- Volume
- 12
- Issue
- 16
- Pages
- 2457-2467
- ISSN
- 1465-6566 (ISSN-L)
- 1744-7666
- OpenAlex
- W2115352662
- Cited by
- 90
- References
- 14
- FWCI
- 11.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacological treatment of generalized anxiety disorder. https://app.cochat.ai/papers/10.1517/14656566.2011.618496
- The paper
- Reinhold, J. A., Mandos, L. A., Rickels, K., & Lohoff, F. W. (2011). Pharmacological treatment of generalized anxiety disorder. Expert Opinion on Pharmacotherapy. https://doi.org/10.1517/14656566.2011.618496
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.